Research programme: protein kinase inhibitors - Millennium/Sunesis/Supernus

Drug Profile

Research programme: protein kinase inhibitors - Millennium/Sunesis/Supernus

Alternative Names: BIIB 024; SNS 229; SNS 510

Latest Information Update: 30 Mar 2016

Price : $50

At a glance

  • Originator Biogen Idec; Sunesis Pharmaceuticals
  • Developer Sunesis Pharmaceuticals; Takeda Oncology
  • Class Pyrazines; Small molecules; Thiazoles
  • Mechanism of Action 3 phosphoinositide dependent protein kinase 1 inhibitors; Protein kinase inhibitors; Proto oncogene protein b raf inhibitors; Raf kinase inhibitors; Ras signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 10 Mar 2016 Sunesis announces intention to submit IND for SNS 229
  • 10 Mar 2016 Sunesis plans IND-enabling toxicology studies for SNS 229
  • 09 Nov 2015 Preclinical studies in Cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top